Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial
MRD negativity 52% versus 38%, OR 1.82, P = 0.012). At current follow-up, PFS data were immature. Grade 3-4 non-hematologic adverse events (AEs), treatment discontinuations and deaths due to AEs were similar in the two arms. Isa-KRd significantly improved NGS-MRD negativity in TE patients with NDMM, with a manageable safety profile. ClinicalTrials.gov registration: NCT04483739 .
Authors
- W Roeloffzen
- Mario Boccadoro (ORCID: https://orcid.org/0000-0001-8130-5209)
- Francesca Gay (ORCID: https://orcid.org/0000-0002-8619-412X)
- Eirini Katodritou (ORCID: https://orcid.org/0000-0001-9404-807X)
- Ka Lung Wu (ORCID: https://orcid.org/0000-0001-6042-978X)
- Marjolein van der Klift (ORCID: https://orcid.org/0000-0003-3333-1327)
- Annemiek Broijl (ORCID: https://orcid.org/0000-0002-0554-8003)
- Elisabetta Antonioli (ORCID: https://orcid.org/0000-0001-5547-3516)
- Angelo Belotti (ORCID: https://orcid.org/0000-0002-0617-3127)
- P. Rodríguez Otero
- J. Radocha
- Mark van Duin
- Luděk Pour
- Niels W. C. J. van de Donk
- Elena M. van Leeuwen-Segarceanu
- Meletios A. Dimopoulos
- Roman Hájek
- Hermann Einsele
- Joaquín Martínez-López
- Pieter Sonneveld
- Fredrik Schjesvold
- Mattia D’Agostino
- Roberto Mina
- Joan Bladé
- Katja C. Weisel
- Elena Zamagni
- Laura Rosiñol
Institutions
- Oslo University Hospital (NO)
- University Medical Center Groningen (NL)
- Universität Hamburg (DE)
- University of Oslo (NO)
- University of Ostrava (CZ)
- Korea University (KR)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Theageneio General Hospital (GR)
- University Hospital Ostrava (CZ)
- Hospital Universitario 12 De Octubre (ES)
- University Hospital Brno (CZ)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- St. Antonius Ziekenhuis (NL)
- Amphia Ziekenhuis (NL)
- Institut Català d'Oncologia (ES)
- University Medical Center Hamburg-Eppendorf (DE)
- Hospital Clínic de Barcelona (ES)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Istituto di Ematologia di Bologna (IT)
- Province of Antwerp (BE)
- Universitätsklinikum Würzburg (DE)
- Clinica Universidad de Navarra (ES)
- University Hospital Hradec Králové (CZ)
- ERN GUARD-Heart (NL)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Enel (Italy) (IT)
- Vrije Universiteit Amsterdam (NL)
- University of Bologna (IT)
Publication Details
- Journal
- Nature Medicine
- Published
- 2026-04-06
- DOI
- https://doi.org/10.1038/s41591-026-04282-0
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00